Adjuvants—a classification and review of their modes of action
Identifieur interne : 001465 ( Istex/Checkpoint ); précédent : 001464; suivant : 001466Adjuvants—a classification and review of their modes of action
Auteurs : John C. Cox [Australie] ; Alan R. Coulter [Australie]Source :
- Vaccine [ 0264-410X ] ; 1997.
English descriptors
- Teeft :
- Adjuvant, Adjuvant activity, Adjuvant effect, Aluminium, Aluminium salts, Amphipathic, Amphipathic molecules, Cell surface, Clinical trial, Copolymer, Coulter, Cytokine, Cytotoxic, Dendritic cells, Derivative, Emulsion, Immun, Immune, Immune response, Immunogen, Immunological, Immunological adjuvants, Immunomodulators, Immunomodulatory, Iscoms, Lipid, Lipophilic, Liposome, Macrophage, Particulate adjuvants, Peptide, Plenum press, Polymer, Saponin, Upregulation, Vaccine.
Abstract
Abstract: Since early this century, various substances have been added to vaccines and certain formulations have been devised in an attempt to render vaccines more effective. Despite a plethora of options, only aluminium salts have gained acceptance as human vaccine adjuvants and even veterinary vaccines are largely dependent upon the use of aluminium salts. Currently, many new vaccines are under development and there is a desire to simplify vaccination schedules both by increasing the number of components per vaccine and decreasing the number of doses required for a vaccine course. New, more effective adjuvants will be required to achieve this.
Url:
DOI: 10.1016/S0264-410X(96)00183-1
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:89BCA1DE9474882AD7A917230234C11697A8A956Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Adjuvants—a classification and review of their modes of action</title><author><name sortKey="Cox, John C" sort="Cox, John C" uniqKey="Cox J" first="John C." last="Cox">John C. Cox</name></author><author><name sortKey="Coulter, Alan R" sort="Coulter, Alan R" uniqKey="Coulter A" first="Alan R." last="Coulter">Alan R. Coulter</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:89BCA1DE9474882AD7A917230234C11697A8A956</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0264-410X(96)00183-1</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-0RBS8B5C-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002592</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002592</idno><idno type="wicri:Area/Istex/Curation">002592</idno><idno type="wicri:Area/Istex/Checkpoint">001465</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001465</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Adjuvants—a classification and review of their modes of action</title><author><name sortKey="Cox, John C" sort="Cox, John C" uniqKey="Cox J" first="John C." last="Cox">John C. Cox</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Immunology Research, CSL Ltd, 45 Poplar Road, Parkville, Vic. 3052</wicri:regionArea><wicri:noRegion>Vic. 3052</wicri:noRegion></affiliation></author><author><name sortKey="Coulter, Alan R" sort="Coulter, Alan R" uniqKey="Coulter A" first="Alan R." last="Coulter">Alan R. Coulter</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Immunology Research, CSL Ltd, 45 Poplar Road, Parkville, Vic. 3052</wicri:regionArea><wicri:noRegion>Vic. 3052</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="248">248</biblScope><biblScope unit="page" to="256">256</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Adjuvant activity</term><term>Adjuvant effect</term><term>Aluminium</term><term>Aluminium salts</term><term>Amphipathic</term><term>Amphipathic molecules</term><term>Cell surface</term><term>Clinical trial</term><term>Copolymer</term><term>Coulter</term><term>Cytokine</term><term>Cytotoxic</term><term>Dendritic cells</term><term>Derivative</term><term>Emulsion</term><term>Immun</term><term>Immune</term><term>Immune response</term><term>Immunogen</term><term>Immunological</term><term>Immunological adjuvants</term><term>Immunomodulators</term><term>Immunomodulatory</term><term>Iscoms</term><term>Lipid</term><term>Lipophilic</term><term>Liposome</term><term>Macrophage</term><term>Particulate adjuvants</term><term>Peptide</term><term>Plenum press</term><term>Polymer</term><term>Saponin</term><term>Upregulation</term><term>Vaccine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Since early this century, various substances have been added to vaccines and certain formulations have been devised in an attempt to render vaccines more effective. Despite a plethora of options, only aluminium salts have gained acceptance as human vaccine adjuvants and even veterinary vaccines are largely dependent upon the use of aluminium salts. Currently, many new vaccines are under development and there is a desire to simplify vaccination schedules both by increasing the number of components per vaccine and decreasing the number of doses required for a vaccine course. New, more effective adjuvants will be required to achieve this.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Cox, John C" sort="Cox, John C" uniqKey="Cox J" first="John C." last="Cox">John C. Cox</name></noRegion><name sortKey="Coulter, Alan R" sort="Coulter, Alan R" uniqKey="Coulter A" first="Alan R." last="Coulter">Alan R. Coulter</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001465 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001465 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:89BCA1DE9474882AD7A917230234C11697A8A956
|texte= Adjuvants—a classification and review of their modes of action
}}
| This area was generated with Dilib version V0.6.33. |  |